Stock Quote
Valeant Pharmaceuticals International (VRX) (NYSE Arca)
$32.49
3:46pm EST
-2.37%
$33.28
$32.15
1,646,514
$32.95
$31.88
$34.44
$15.64
0.55
679,128
VRX
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Pearson, J. Michael | Chairman of the Board, Chief Executive Officer | 9,767,390 |
| Chaudhuri, Bhaskar | President | -- |
| Blott, Peter | Chief Financial Officer, Executive Vice President | 1,137,060 |
Profile
Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty... Full Description
Company Address
Valeant Pharmaceuticals International
One Enterprise
Aliso Viejo CA 92656
P: +1949.4616000
One Enterprise
Aliso Viejo CA 92656
P: +1949.4616000
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Eisai Co., Ltd | ¥3,210.00 | +10.00 |
| UCB SA | €30.68 | +0.08 |
| Novartis AG | CHF55.15 | +1.20 |
| VRX | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.57 |
| P/S(TTM) | 3.50 | 0.57 |
| ROI(TTM) | -4.21 | 1.86 |
| ROE(TTM) | -10.33 | 2.51 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | 0.54 |
| EPS Est. (Current Year) | 2.13 |
| Total Revenue | $220.32M |
| Net Income | $37.63M |
| EPS | $0.45 |
